Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PLK1 | P53350 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22223910 | 0.86 | EPHX2 (0.74) | SMN1; SMN2HPGDNPC1RAB9AEPHX2 | |
| SCHEMBL21275528 | 0.85 | PARP10 (0.58) | PARP10SMN1; SMN2ALDH1A1LMNANPC1 | |
| SCHEMBL12209632 | 0.84 | HPGD (0.53) | PARP10SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL14161002 | 0.84 | PARP10 (0.61) | PARP10SMN1; SMN2HTTALDH1A1LMNA | |
| SCHEMBL22192684 | 0.83 | NPC1 (0.61) | PARP10SMN1; SMN2ALDH1A1LMNANPC1 | |
| SCHEMBL7326433 | 0.82 | PARP10 (0.58) | PARP10SMN1; SMN2ALDH1A1LMNANPC1 | |
| SCHEMBL15830297 | 0.82 | PARP10 (0.58) | PARP10SMN1; SMN2ALDH1A1LMNANPC1 | |
| SCHEMBL21275532 | 0.82 | KMT2A (0.53) | PARP10SMN1; SMN2HTTALDH1A1LMNA | |
| SCHEMBL11576648 | 0.81 | PARP10 (0.66) | PARP10SMN1; SMN2ALDH1A1LMNANPC1 | |
| SCHEMBL8339652 | 0.80 | PARP10 (0.60) | PARP10SMN1; SMN2ALDH1A1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564914-B2 | Methods of treating bone loss | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-31 | — | — | US | disclosed |
| US-11123311-B2 | Methods of treating mental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-10-01 | — | — | US | disclosed |
| US-10383835-B2 | Treatment of inflammatory disorders in non-human mammals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2675274-B1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | UNIV CALIFORNIA (US) | 2017-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | EPHX1, NCEH1, SOST | PARP10 3599/4885SMN1; SMN2 4135/4885HTT 4850/4885 |
| US-11564914-B2 | Methods of treating bone loss | EPHX1, NCEH1, SOST | PARP10 3599/4885SMN1; SMN2 4135/4885HTT 4850/4885 |
| US-11123311-B2 | Methods of treating mental disorders | FAAH, EPHX1, FAAH2 | PARP10 4139/4885SMN1; SMN2 4001/4885HTT 2272/4885 |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | PARP10 4139/4885SMN1; SMN2 4001/4885HTT 2272/4885 |
| US-10383835-B2 | Treatment of inflammatory disorders in non-human mammals | EPHX1, SERPINB1, PTGES | PARP10 2868/4885SMN1; SMN2 1494/4885HTT 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.